<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04327011</url>
  </required_header>
  <id_info>
    <org_study_id>Tg 511-09-01</org_study_id>
    <nct_id>NCT04327011</nct_id>
  </id_info>
  <brief_title>A Continuation Protocol for Patients Previously Enrolled in a Study of Toca 511</brief_title>
  <official_title>A Continuation Protocol for Patients Previously Enrolled in a Study of Toca 511</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tocagen Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tocagen Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicenter, open-label, continuation study to allow subjects who have previously
      received Toca 511 to continue to receive Toca FC and to allow for extended safety
      observations. Subjects will be seen on an every six week basis for 1 year or longer. Subjects
      who continue to receive Toca FC will receive the dose described in the &quot;parent&quot; protocol. If
      the Toca FC dose is adjusted for any reason, the serum concentration will be monitored.
      Gadolinium (Gd)-enhanced magnetic resonance imaging (MRI) scans will be performed as per
      standard of care.

      If the subject has recurred/progressed, repeat intracranial injection of Toca 511 followed by
      Toca FC treatment may be offered to consenting patients.

      Subjects who enter the study to continue Toca FC and subsequently discontinue Toca FC, and
      subjects who are only willing or able to perform limited testing will have viral testing
      alone, at the appropriate intervals.

      After the first year, subjects will be seen twice yearly for the next 4 years and then
      contacted yearly for the next 10 years.

      All subjects will be followed on study for at least 5 years regardless of whether they are
      taking Toca FC.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Sponsor decision
  </why_stopped>
  <start_date type="Actual">February 2011</start_date>
  <completion_date type="Actual">December 2019</completion_date>
  <primary_completion_date type="Actual">December 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Long term safety follow up</measure>
    <time_frame>From study entry up to 15 years</time_frame>
    <description>This will be based on treatment emergent adverse events, clinical laboratory values and viral testing.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival in days from the initial Toca 511 administration on parent study to the date of death.</measure>
    <time_frame>From initial Toca 511 administration to death of last patient alive for up to 15 years.</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Progression-free survival in days from the initial Toca 511 administration on parent study to confirmed disease progression or death from any cause.</measure>
    <time_frame>from initial toca 511 administration to time of progression or death of any cause for up to 15 years.</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Objective response rate from initial dose of Toca FC from the parent protocol</measure>
    <time_frame>Time from initial dose of Toca FC to death of last patient alive for up to 15 years.</time_frame>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">65</enrollment>
  <condition>Glioblastoma Multiforme</condition>
  <condition>Astrocytoma</condition>
  <condition>Gliomas, Malignant</condition>
  <arm_group>
    <arm_group_label>Experimental</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single arm Toca 511 vector/5-FC prodrug</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Toca 511 vector</intervention_name>
    <description>Toca 511 consists of a purified retroviral replicating vector encoding a modified yeast cytosine deaminase (CD) gene. The CD gene converts the antifungal 5-flurocytosine (5FC) to the anticancer drug 5-FU in cells that have been infected by the Toca 511 vector</description>
    <arm_group_label>Experimental</arm_group_label>
    <other_name>vocimagene amiretrorepvec</other_name>
    <other_name>RRV</other_name>
    <other_name>retroviral replicating virus</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Toca FC • Flucytosine • 5-FC • 5-Fluorocytosine</intervention_name>
    <description>Toca FC is an extended-release formulation of flucytosine.</description>
    <arm_group_label>Experimental</arm_group_label>
    <other_name>Extended Release 5-FC</other_name>
    <other_name>5-FC</other_name>
    <other_name>5-Fluorocytosine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Informed Consent Form

          -  Subject received Toca 511 in prior study.

          -  Subject is willing to abide by protocol

        Exclusion Criteria:

          -  Subject has history of allergy or intolerance to flucytosine
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Asha Das, MD</last_name>
    <role>Study Director</role>
    <affiliation>Tocagen Inc.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Michael Vogelbaum, MD, PhD, NS</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Cleveland Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California, Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCSD</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92093</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCSF</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Henry Ford Health System</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JFK Medical Center Neuroscience Institute</name>
      <address>
        <city>Edison</city>
        <state>New Jersey</state>
        <zip>08820</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hackensack University Medical Center</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>John Theurer Cancer Center at Hackensack University</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Foundation</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ohio State University</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh Medical Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Swedish Neuroscience Institute</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98122</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>December 21, 2016</study_first_submitted>
  <study_first_submitted_qc>March 26, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 30, 2020</study_first_posted>
  <last_update_submitted>March 26, 2020</last_update_submitted>
  <last_update_submitted_qc>March 26, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>glioma</keyword>
  <keyword>glioblastoma</keyword>
  <keyword>glioblastoma multiforme</keyword>
  <keyword>Grade IV astrocytoma</keyword>
  <keyword>brain cancer</keyword>
  <keyword>recurrent glioblastoma</keyword>
  <keyword>GBM</keyword>
  <keyword>AA</keyword>
  <keyword>AOD</keyword>
  <keyword>anaplastic astrocytoma</keyword>
  <keyword>anaplastic oligodendroglioma</keyword>
  <keyword>anaplastic oligoastrocytoma</keyword>
  <keyword>high grade glioma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioblastoma</mesh_term>
    <mesh_term>Glioma</mesh_term>
    <mesh_term>Astrocytoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Flucytosine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

